Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Analgesic Research In Brief

This article was originally published in The Tan Sheet

Executive Summary

Ibuprofen in children: Compared with acetaminophen, ibuprofen may reduce risk of morbidity from asthma among children not known to be sensitive to aspirin or NSAIDs, Samuel Lesko, MD, et al., state in February Pediatrics. Analysis looked at 1,879 asthmatic children participating in the Boston University Fever Study. Acetaminophen 5 mg/kg, ibuprofen 5 mg/kg or ibuprofen 10 mg/kg were provided to parents of 632, 636 and 611 children on asthma medications, respectively. In the next month, children taking either dose of ibuprofen were 44% less likely to have an outpatient visit for asthma than children taking acetaminophen. Hospitalization rates were 37% lower among ibuprofen users, but deemed statistically insignificant. Since no placebo was used, researchers note it is impossible to determine whether "acetaminophen increased or ibuprofen decreased short-term asthma morbidity." Boots Healthcare International, which makes ibuprofen-containing Nurofen, sponsored the study...

You may also be interested in...

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts